LumaCina was formed by the investment firm Bridgewest Group in 2023 to be a global supplier of high-quality sterile injectable pharmaceutical products. Bridgewest Group is a $3B privately held investment group, which has been building, scaling, and operating businesses in the life sciences industry for over 20 years. Bridgewest’s portfolio spans the entire life science industry from preclinical drug discovery platforms to large, scaled contract development and manufacturing organizations.

In forming LumaCina Bridgewest has brought together a best-in-class manufacturing facility that was formerly part of the Pfizer global manufacturing network, a tenured and experienced operations team, top-level research and development capabilities, and a world-class management team. The LumaCina team has decades of experience in developing, marketing, and distributing pharmaceutical products and has shipped products to 98 countries around the world including the United States, European Union, and Asian Pacific Nations

LumaCina currently offers a portfolio of sterile injectable drugs that was divested by Pfizer and has a robust pipeline of products in development that we will bring to regulated and semi-regulated markets around the world. These include dosage forms in multi-dose vials, multiple presentations withing the blow-fill-seal offering, and small molecule cytotoxic products.